Adverum Biotechnologies, Inc. (ADVM) Financials

ADVM Assets vs Liabilities
DateAssetsLiabilities
Sept. 30, 2024 234.4 million 90.3 million
June 30, 2024 253.8 million 85.8 million
March 31, 2024 267.8 million 85.5 million
Dec. 31, 2023 173.0 million 89.5 million

ADVM Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2024 -21.3 million 3.0 million
June 30, 2024 -19.9 million 3.9 million
March 31, 2024 -23.3 million 4.2 million
Dec. 31, 2023 -21.6 million 4.1 million

ADVM Net Income

No data available :(

ADVM Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2024 153.2 million 125.2 million 62.6 million
June 30, 2024 173.8 million 63.3 million 73.9 million
March 31, 2024 193.3 million 64.0 million 74.5 million
Dec. 31, 2023 96.5 million 64.6 million 75.0 million

ADVM Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2024 20.9 million
June 30, 2024 20.9 million
March 31, 2024 16.5 million
Dec. 31, 2023 10.1 million

ADVM Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2024 221000 20.4 million 9.8 million -
June 30, 2024 16000 17.1 million 11.0 million 7.2 million
March 31, 2024 90000 15.4 million 11.7 million 303000
Dec. 31, 2023 192000 15.1 million 9.9 million -1.0 million

ADVM Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2024 1.0 million 890000
June 30, 2024 - 956000
March 31, 2024 - 997000
Dec. 31, 2023 -3.6 million 1.0 million

ADVM

Price: $4.36

52 week price:
1.78
6.12

Earnings Per Share: -8.57 USD

P/E Ratio: -0.49

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 198800

Ebitda: -14.0 million

Market Capitalization: 92.1 million

Links: